Tokyo Tape
Sign in
← M3

Quarterly report · Q1

2413.TEDINET S100RK8S
Period2023-04-01 → 2023-06-30
Filed2023-08-10
StandardIFRS
ConsolidatedYes
Data checks12 of 12 passed
Key figures · 47
MetricValuePeriodScopeSource row
Revenue¥57.4bn2023-04-01 → 2023-06-30Cons.Revenue IFRS
Revenue¥230.8bn2022-04-01 → 2023-03-31Cons.Revenue IFRS (5-year summary)
Revenue¥57.0bn2022-04-01 → 2022-06-30Cons.Revenue IFRS
Operating income¥18.0bn2023-04-01 → 2023-06-30Cons.Operating profit loss IFRS
Operating income¥18.7bn2022-04-01 → 2022-06-30Cons.Operating profit loss IFRS
Profit before tax¥19.8bn2023-04-01 → 2023-06-30Cons.Profit loss before tax IFRS
Profit before tax¥74.3bn2022-04-01 → 2023-03-31Cons.Profit loss before tax IFRS (5-year summary)
Profit before tax¥19.7bn2022-04-01 → 2022-06-30Cons.Profit loss before tax IFRS
Net income (owners)¥12.4bn2023-04-01 → 2023-06-30Cons.Profit loss attributable to owners of parent IFRS
Net income (owners)¥49.0bn2022-04-01 → 2023-03-31Cons.Profit loss attributable to owners of parent IFRS (5-year summary)
Net income (owners)¥12.1bn2022-04-01 → 2022-06-30Cons.Profit loss attributable to owners of parent IFRS
Net income¥13.6bn2023-04-01 → 2023-06-30Cons.Profit loss IFRS
Net income¥13.5bn2022-04-01 → 2022-06-30Cons.Profit loss IFRS
Total assets¥439.6bnat 2023-06-30Cons.Assets IFRS
Total assets¥400.6bnat 2023-03-31Cons.Assets IFRS
Total assets¥357.5bnat 2022-06-30Cons.Total assets IFRS (5-year summary)
Total liabilities¥110.9bnat 2023-06-30Cons.Liabilities IFRS
Total liabilities¥91.1bnat 2023-03-31Cons.Liabilities IFRS
Net assets / equity¥328.8bnat 2023-06-30Cons.Equity IFRS
Net assets / equity¥309.5bnat 2023-03-31Cons.Equity IFRS
Net assets / equity¥275.1bnat 2022-06-30Cons.Equity IFRS
Net assets / equity¥264.0bnat 2022-03-31dCons.Equity IFRS
Equity (owners)¥316.8bnat 2023-06-30Cons.Equity attributable to owners of parent IFRS
Equity (owners)¥302.6bnat 2023-03-31Cons.Equity attributable to owners of parent IFRS
Equity (owners)¥268.8bnat 2022-06-30Cons.Equity attributable to owners of parent IFRS (5-year summary)
Cash & equivalents¥130.7bnat 2023-06-30Cons.Cash and cash equivalents IFRS
Cash & equivalents¥118.3bnat 2023-03-31Cons.Cash and cash equivalents IFRS
Cash & equivalents¥88.8bnat 2022-06-30Cons.Cash and cash equivalents IFRS
Cash & equivalents¥104.3bnat 2022-03-31dCons.Cash and cash equivalents IFRS
Operating cash flow¥12.0bn2023-04-01 → 2023-06-30Cons.Net cash provided by used in operating activities IFRS
Operating cash flow¥57.1bn2022-04-01 → 2023-03-31Cons.Cash flows from used in operating activities IFRS (5-year summary)
Operating cash flow¥9.4bn2022-04-01 → 2022-06-30Cons.Net cash provided by used in operating activities IFRS
Investing cash flow−¥18.2bn2023-04-01 → 2023-06-30Cons.Net cash provided by used in investing activities IFRS
Investing cash flow−¥21.9bn2022-04-01 → 2023-03-31Cons.Cash flows from used in investing activities IFRS (5-year summary)
Investing cash flow−¥14.7bn2022-04-01 → 2022-06-30Cons.Net cash provided by used in investing activities IFRS
Financing cash flow¥16.4bn2023-04-01 → 2023-06-30Cons.Net cash provided by used in financing activities IFRS
Financing cash flow−¥22.8bn2022-04-01 → 2023-03-31Cons.Cash flows from used in financing activities IFRS (5-year summary)
Financing cash flow−¥12.5bn2022-04-01 → 2022-06-30Cons.Net cash provided by used in financing activities IFRS
EPS (basic)¥18.292023-04-01 → 2023-06-30Cons.Basic earnings loss per share IFRS
EPS (basic)¥72.222022-04-01 → 2023-03-31Cons.Basic earnings loss per share IFRS (5-year summary)
EPS (basic)¥17.862022-04-01 → 2022-06-30Cons.Basic earnings loss per share IFRS
EPS (diluted)¥18.272023-04-01 → 2023-06-30Cons.Diluted earnings loss per share IFRS
EPS (diluted)¥72.172022-04-01 → 2023-03-31Cons.Diluted earnings loss per share IFRS (5-year summary)
EPS (diluted)¥17.852022-04-01 → 2022-06-30Cons.Diluted earnings loss per share IFRS
Equity ratio72.1%at 2023-06-30Cons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio75.5%at 2023-03-31Cons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio75.2%at 2022-06-30Cons.Ratio of owners equity to gross assets IFRS (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 54
SegmentItemPeriodValue
Reconciling Itemsreconcilingrevenue2023-04-01 → 2023-06-30−¥1.0bn
Reconciling Itemsreconcilingrevenue intersegment2023-04-01 → 2023-06-30−¥1.0bn
Reconciling Itemsreconcilingsegment profit2023-04-01 → 2023-06-30¥167m
jpcrp040300-q1r_E05425-000Career Solutionreportable segmentrevenue2023-04-01 → 2023-06-30¥5.6bn
jpcrp040300-q1r_E05425-000Career Solutionreportable segmentrevenue external2023-04-01 → 2023-06-30¥5.6bn
jpcrp040300-q1r_E05425-000Career Solutionreportable segmentrevenue intersegment2023-04-01 → 2023-06-30¥16m
jpcrp040300-q1r_E05425-000Career Solutionreportable segmentsegment profit2023-04-01 → 2023-06-30¥2.7bn
jpcrp040300-q1r_E05425-000Evidence Solutionreportable segmentrevenue2023-04-01 → 2023-06-30¥7.0bn
jpcrp040300-q1r_E05425-000Evidence Solutionreportable segmentrevenue external2023-04-01 → 2023-06-30¥6.8bn
jpcrp040300-q1r_E05425-000Evidence Solutionreportable segmentrevenue intersegment2023-04-01 → 2023-06-30¥114m
jpcrp040300-q1r_E05425-000Evidence Solutionreportable segmentsegment profit2023-04-01 → 2023-06-30¥1.9bn
jpcrp040300-q1r_E05425-000Medical Platformreportable segmentrevenue2023-04-01 → 2023-06-30¥21.9bn
jpcrp040300-q1r_E05425-000Medical Platformreportable segmentrevenue external2023-04-01 → 2023-06-30¥21.1bn
jpcrp040300-q1r_E05425-000Medical Platformreportable segmentrevenue intersegment2023-04-01 → 2023-06-30¥868m
jpcrp040300-q1r_E05425-000Medical Platformreportable segmentsegment profit2023-04-01 → 2023-06-30¥8.9bn
jpcrp040300-q1r_E05425-000Overseasreportable segmentrevenue2023-04-01 → 2023-06-30¥15.7bn
jpcrp040300-q1r_E05425-000Overseasreportable segmentrevenue external2023-04-01 → 2023-06-30¥15.7bn
jpcrp040300-q1r_E05425-000Overseasreportable segmentrevenue intersegment2023-04-01 → 2023-06-30¥11m
jpcrp040300-q1r_E05425-000Overseasreportable segmentsegment profit2023-04-01 → 2023-06-30¥3.7bn
jpcrp040300-q1r_E05425-000Site Solutionreportable segmentrevenue2023-04-01 → 2023-06-30¥7.7bn
jpcrp040300-q1r_E05425-000Site Solutionreportable segmentrevenue external2023-04-01 → 2023-06-30¥7.7bn
jpcrp040300-q1r_E05425-000Site Solutionreportable segmentrevenue intersegment2023-04-01 → 2023-06-30¥3m
jpcrp040300-q1r_E05425-000Site Solutionreportable segmentsegment profit2023-04-01 → 2023-06-30¥831m
—segment totalrevenue2023-04-01 → 2023-06-30¥57.9bn
—segment totalrevenue external2023-04-01 → 2023-06-30¥56.9bn
—segment totalrevenue intersegment2023-04-01 → 2023-06-30¥1.0bn
—segment totalsegment profit2023-04-01 → 2023-06-30¥18.0bn
Reconciling Itemsreconcilingrevenue2022-04-01 → 2022-06-30−¥1.7bn
Reconciling Itemsreconcilingrevenue intersegment2022-04-01 → 2022-06-30−¥1.7bn
Reconciling Itemsreconcilingsegment profit2022-04-01 → 2022-06-30−¥471m
jpcrp040300-q1r_E05425-000Career Solutionreportable segmentrevenue2022-04-01 → 2022-06-30¥5.5bn
jpcrp040300-q1r_E05425-000Career Solutionreportable segmentrevenue external2022-04-01 → 2022-06-30¥5.2bn
jpcrp040300-q1r_E05425-000Career Solutionreportable segmentrevenue intersegment2022-04-01 → 2022-06-30¥267m
jpcrp040300-q1r_E05425-000Career Solutionreportable segmentsegment profit2022-04-01 → 2022-06-30¥2.8bn
jpcrp040300-q1r_E05425-000Evidence Solutionreportable segmentrevenue2022-04-01 → 2022-06-30¥7.2bn
jpcrp040300-q1r_E05425-000Evidence Solutionreportable segmentrevenue external2022-04-01 → 2022-06-30¥7.0bn
jpcrp040300-q1r_E05425-000Evidence Solutionreportable segmentrevenue intersegment2022-04-01 → 2022-06-30¥162m
jpcrp040300-q1r_E05425-000Evidence Solutionreportable segmentsegment profit2022-04-01 → 2022-06-30¥2.2bn
jpcrp040300-q1r_E05425-000Medical Platformreportable segmentrevenue2022-04-01 → 2022-06-30¥20.2bn
jpcrp040300-q1r_E05425-000Medical Platformreportable segmentrevenue external2022-04-01 → 2022-06-30¥19.3bn
jpcrp040300-q1r_E05425-000Medical Platformreportable segmentrevenue intersegment2022-04-01 → 2022-06-30¥951m
jpcrp040300-q1r_E05425-000Medical Platformreportable segmentsegment profit2022-04-01 → 2022-06-30¥8.8bn
jpcrp040300-q1r_E05425-000Overseasreportable segmentrevenue2022-04-01 → 2022-06-30¥14.9bn
jpcrp040300-q1r_E05425-000Overseasreportable segmentrevenue external2022-04-01 → 2022-06-30¥14.9bn
jpcrp040300-q1r_E05425-000Overseasreportable segmentrevenue intersegment2022-04-01 → 2022-06-30¥2m
jpcrp040300-q1r_E05425-000Overseasreportable segmentsegment profit2022-04-01 → 2022-06-30¥4.0bn
jpcrp040300-q1r_E05425-000Site Solutionreportable segmentrevenue2022-04-01 → 2022-06-30¥10.2bn
jpcrp040300-q1r_E05425-000Site Solutionreportable segmentrevenue external2022-04-01 → 2022-06-30¥9.9bn
jpcrp040300-q1r_E05425-000Site Solutionreportable segmentrevenue intersegment2022-04-01 → 2022-06-30¥304m
jpcrp040300-q1r_E05425-000Site Solutionreportable segmentsegment profit2022-04-01 → 2022-06-30¥1.4bn
—segment totalrevenue2022-04-01 → 2022-06-30¥58.0bn
—segment totalrevenue external2022-04-01 → 2022-06-30¥56.3bn
—segment totalrevenue intersegment2022-04-01 → 2022-06-30¥1.7bn
—segment totalsegment profit2022-04-01 → 2022-06-30¥19.3bn

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 587
ItemContextValueUnit
Operating profit loss IFRSPrior1YTDDuration18695000000JPY
Operating profit loss IFRSCurrentYTDDuration18004000000JPY
Finance income IFRSPrior1YTDDuration1069000000JPY
Finance income IFRSCurrentYTDDuration1892000000JPY
Finance costs IFRSPrior1YTDDuration16000000JPY
Finance costs IFRSCurrentYTDDuration65000000JPY
Profit loss before tax IFRSPrior1YTDDuration19748000000JPY
Profit loss before tax IFRSCurrentYTDDuration19831000000JPY
Income tax expense IFRSPrior1YTDDuration6260000000JPY
Income tax expense IFRSCurrentYTDDuration6277000000JPY
Profit loss IFRSPrior1YTDDuration13487000000JPY
Profit loss IFRSCurrentYTDDuration13554000000JPY
Profit loss attributable to owners of parent IFRSPrior1YTDDuration12127000000JPY
Profit loss attributable to owners of parent IFRSCurrentYTDDuration12414000000JPY
Profit loss attributable to non controlling interests IFRSPrior1YTDDuration1360000000JPY
Profit loss attributable to non controlling interests IFRSCurrentYTDDuration1140000000JPY
Profit loss IFRSPrior1YTDDuration13487000000JPY
Profit loss IFRSCurrentYTDDuration13554000000JPY
Basic earnings loss per share IFRSPrior1YTDDuration17.86
Basic earnings loss per share IFRSCurrentYTDDuration18.29
Diluted earnings loss per share IFRSPrior1YTDDuration17.85
Diluted earnings loss per share IFRSCurrentYTDDuration18.27
Profit loss IFRSPrior1YTDDuration13487000000JPY
Profit loss IFRSCurrentYTDDuration13554000000JPY
Remeasurements of defined benefit plans net of tax items that will not be reclassified to profit or loss oci IFRSPrior1YTDDuration－JPY
Remeasurements of defined benefit plans net of tax items that will not be reclassified to profit or loss oci IFRSCurrentYTDDuration-2000000JPY
Net change in fair value of equity instruments designated as measured at fair value through other comprehensive income net of tax items that will not be reclassified to profit or loss oci IFRSPrior1YTDDuration29000000JPY
Net change in fair value of equity instruments designated as measured at fair value through other comprehensive income net of tax items that will not be reclassified to profit or loss oci IFRSCurrentYTDDuration108000000JPY
Total of items that will not be reclassified to profit or loss oci IFRSPrior1YTDDuration29000000JPY
Total of items that will not be reclassified to profit or loss oci IFRSCurrentYTDDuration106000000JPY
Exchange differences on translation of foreign operations net of tax items that may be reclassified to profit or loss oci IFRSPrior1YTDDuration6183000000JPY
Exchange differences on translation of foreign operations net of tax items that may be reclassified to profit or loss oci IFRSCurrentYTDDuration7752000000JPY
Share of other comprehensive income of investments accounted for using equity method net of tax items that may be reclassified to profit or loss oci IFRSPrior1YTDDuration3561000000JPY
Share of other comprehensive income of investments accounted for using equity method net of tax items that may be reclassified to profit or loss oci IFRSCurrentYTDDuration1636000000JPY
Total of items that may be reclassified to profit or loss oci IFRSPrior1YTDDuration9744000000JPY
Total of items that may be reclassified to profit or loss oci IFRSCurrentYTDDuration9388000000JPY
Other comprehensive income IFRSPrior1YTDDuration9773000000JPY
Other comprehensive income IFRSCurrentYTDDuration9495000000JPY
Comprehensive income IFRSPrior1YTDDuration23261000000JPY
Comprehensive income IFRSCurrentYTDDuration23049000000JPY
Comprehensive income attributable to owners of parent IFRSPrior1YTDDuration21692000000JPY
Comprehensive income attributable to owners of parent IFRSCurrentYTDDuration21676000000JPY
Comprehensive income attributable to non controlling interests IFRSPrior1YTDDuration1568000000JPY
Comprehensive income attributable to non controlling interests IFRSCurrentYTDDuration1373000000JPY
Comprehensive income IFRSPrior1YTDDuration23261000000JPY
Comprehensive income IFRSCurrentYTDDuration23049000000JPY
Equity IFRSPrior2YearInstant_ShareCapitalIFRSMember29129000000JPY
Equity IFRSPrior2YearInstant_CapitalSurplusIFRSMember29704000000JPY
Equity IFRSPrior2YearInstant_TreasurySharesIFRSMember-36000000JPY
Equity IFRSPrior2YearInstant_OtherComponentsOfEquityIFRSMember6131000000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 12 of 12 passed
balance sheet identityconsolidated 2023-03-31pass rounding
balance sheet identityconsolidated 2023-06-30pass
dei present pass
period resolution pass
statement vs summary · net income attributable to parentconsolidated 2022-04-01/2022-06-30pass
statement vs summary · net income attributable to parentconsolidated 2023-04-01/2023-06-30pass
statement vs summary · operating cash flowconsolidated 2022-04-01/2022-06-30pass
statement vs summary · operating cash flowconsolidated 2023-04-01/2023-06-30pass
statement vs summary · revenueconsolidated 2022-04-01/2022-06-30pass
statement vs summary · revenueconsolidated 2023-04-01/2023-06-30pass
statement vs summary · total assetsconsolidated 2023-03-31pass
statement vs summary · total assetsconsolidated 2023-06-30pass